Ototoxic medication list

An ototoxic medication list is a clinical reference of drugs that can damage hearing or balance, grouped by drug class, risk level, and reversibility. The highest-risk groups are aminoglycoside antibiotics, platinum chemotherapy such as cisplatin, and loop diuretics. Salicylates, NSAIDs, antimalarials, and vancomycin carry lower or more variable risk.

More than 200 medications carry documented ototoxic warnings. Audiology and ENT practices, pharmacists, and prescribers use this template to screen patients before high-risk therapy starts. It also gives them one place to record baseline audiometry and every monitoring test that follows.

Key takeaways

Ototoxic medication lists catalog drugs by class, risk level, and reversibility, so high-risk patients are flagged before treatment starts.

Aminoglycosides, cisplatin, and loop diuretics carry the highest risk of cochlear and vestibular damage.

ASHA recommends baseline audiometry before ototoxic treatment, monitoring during therapy, and follow-up after the last dose.

A confirmed 20 dB drop at one frequency, 10 dB at two adjacent frequencies, or lost responses at three consecutive frequencies warrants referral.

Practice software such as Pabau keeps screening forms, audiograms, and monitoring dates on one patient record.

What is an ototoxic medication list?

An ototoxic medication list identifies drugs that damage the cochlea or the vestibular system. The result can be sensorineural hearing loss, tinnitus, vertigo, or balance problems.

The list groups medications by how they cause harm. Aminoglycosides destroy outer hair cells through free radical generation, loop diuretics disrupt the stria vascularis, and platinum compounds trigger hair cell death. It also records whether the hearing loss is usually reversible or permanent.

Practices use it to flag high-risk patients before a drug starts, order baseline hearing tests, and schedule serial audiometry. Testing intervals follow guidance from the American Speech-Language-Hearing Association (ASHA) and the American Academy of Audiology (AAA).

Ototoxic drugs by class at a glance

The table below summarizes the main ototoxic drug classes, the part of the ear each one usually affects, and how often the damage reverses.

How to use the template in five steps

Step 1: Download the template PDF. Open it in your clinical documentation system, or print it for paper-based screening.

Step 2: Review the drug class table and cross-reference every medication the patient takes or is about to start. Mark the risk level (high, moderate, or low) and whether the effect is reversible or permanent.

Step 3: Use the risk factors checklist to identify conditions that amplify ototoxic exposure. These include renal impairment, pre-existing hearing loss, concurrent ototoxic drugs, age, and cumulative dose.

Step 4: Schedule baseline audiometry, including extended high-frequency testing, before the drug starts. Prioritize patients at high risk or on more than one ototoxic drug.

Step 5: Record the baseline result and the planned monitoring dates in the patient record. Keep the completed template as evidence of patient counseling and of monitoring that follows best-practice guidance.

High-risk drug classes: Aminoglycosides, loop diuretics, and chemotherapy

Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin, kanamycin) cause dose- and duration-dependent cochlear hair cell death. Vestibular damage affects a meaningful proportion of patients, and the rate varies by drug. Gentamicin is the most vestibulotoxic. Hearing loss from aminoglycosides is usually permanent and starts at the high frequencies.

Loop diuretics (furosemide, ethacrynic acid, bumetanide, torsemide) can cause rapid, often reversible tinnitus and hearing loss. Risk rises with high doses and rapid infusion rates. Ethacrynic acid carries the highest ototoxic risk in this class. Given alongside aminoglycosides, loop diuretics amplify the damage synergistically.

Platinum-based chemotherapy can cause cumulative, usually permanent high-frequency sensorineural hearing loss. Cisplatin is the main concern, carboplatin carries a lower risk, and oxaliplatin rarely affects hearing. Cisplatin-related hearing loss affects a substantial share of patients, and the share is higher in children.

Oncology teams can write the audiology schedule into each patient’s cancer nursing care plan, so baseline and follow-up tests line up with chemotherapy cycles.

NSAIDs, antimalarials, and moderate-risk medication groups

Salicylates and NSAIDs (aspirin, ibuprofen, naproxen) cause dose-dependent tinnitus that is usually reversible at therapeutic doses. Aspirin is the most recognized example, and its tinnitus often resolves within 48 hours of reducing or stopping the dose.

Antimalarials (quinine, chloroquine, hydroxychloroquine) and vancomycin, a glycopeptide antibiotic, carry documented cochlear and vestibular risk. The risk is highest when kidney function is impaired. Hydroxychloroquine use in rheumatology and lupus care may warrant audiological review where hearing symptoms occur.

For rheumatology patients, the RA medication list and SLE medication list track hydroxychloroquine alongside their other long-term therapies.

Risk factors that amplify ototoxic exposure

Certain patient characteristics sharply increase ototoxic risk, even at standard doses.

• Renal impairment: Reduced clearance of aminoglycosides and loop diuretics prolongs drug exposure and raises peak serum concentrations.
• Pre-existing hearing loss: Patients with baseline sensorineural loss are more susceptible to further threshold shifts.
• Concurrent ototoxic agents: Damage compounds when a patient takes two ototoxic drugs together, such as an aminoglycoside with a loop diuretic.
• Cumulative dose: Duration and total dose are the main drivers of aminoglycoside and cisplatin ototoxicity.
• Age: Older adults and newborns show heightened cochlear vulnerability.
• Genetic susceptibility: Certain mitochondrial mutations increase the risk of aminoglycoside ototoxicity.

Audiological monitoring protocols and referral criteria

ASHA and AAA guidance recommends baseline audiometry before ototoxic treatment starts in high-risk patients. Testing should cover frequencies up to 8 kHz, plus extended high-frequency testing up to 20 kHz where available.

Timing depends on the drug class. For aminoglycosides, ASHA recommends a baseline within 24 hours of the first dose, regular monitoring during therapy, and post-treatment follow-up.

For cisplatin, ASHA recommends a baseline before treatment, monitoring before or around each cycle, and follow-up after treatment ends. Follow-up matters because hearing loss can appear after the last dose. Loop diuretic monitoring may be less frequent unless high doses or rapid infusion are used.

The chart below maps that schedule against the shifts that count as significant under ASHA’s 1994 guideline.

Under that guideline, a change is significant when a repeat test confirms any of these shifts from baseline:

• A decrease of 20 dB or more at any one test frequency.
• A decrease of 10 dB or more at any two adjacent test frequencies.
• Loss of response at three consecutive test frequencies where the patient responded at baseline.

A significant change triggers referral to audiology. The prescriber then decides whether to adjust the dose, switch drugs, or stop treatment.

Who the list is for

Audiology practices use the template for intake screening and baseline documentation. It helps them spot patients on ototoxic regimens quickly and book the right monitoring.

Pharmacists use the list during medication reviews, especially in hospitals, long-term care facilities, and polypharmacy cases. Those are the settings where several ototoxic drugs are most likely to be co-prescribed. A drug card for each high-risk agent keeps dosing and contraindications at hand.

Prescribers, including physicians, physician assistants, nurse practitioners, and midwives, use it as a counseling aid before high-risk therapy starts. It also documents informed consent and monitoring expectations in the patient record.

Benefits of a structured screening template

A systematic list makes it less likely that ototoxic exposure goes unnoticed. Baseline audiometry gets ordered before the drug starts, instead of being found missing after a threshold shift.

Documented screening and monitoring dates show best-practice compliance during audits and quality reviews. Clinicians can show they identified the risk, counseled the patient, and scheduled serial testing on time.

For patients, structured documentation spells out which symptoms need an urgent audiology referral. Tinnitus, muffled hearing, and vertigo are the main ones, and prompt reporting avoids delays in changing the dose.

What to document for ototoxicity screening

Every patient starting an ototoxic medication should have a baseline audiogram in the clinical record. Record the test date, the frequency range tested, and any pre-existing hearing loss or tinnitus.

Document monitoring dates, referral thresholds, and the symptom-reporting advice you gave when the drug started. That record protects the practice if ototoxicity is found later and a liability claim follows.

How Pabau keeps ototoxicity monitoring on schedule

Ototoxic monitoring often lives in three places at once. The screening checklist is on paper, the test dates sit in a spreadsheet, and the audiograms are filed somewhere else. A missed retest only surfaces when someone cross-checks all three.

Pabau, the practice management platform we build, brings those pieces into one patient record. Its patient intake software collects current medications before the first visit. The audiologist sees a gentamicin or cisplatin course before testing begins.

Each baseline audiogram, follow-up appointment, and referral letter then sits on the patient’s timeline in Pabau’s medical records management tools. Automated SMS and email reminders bring patients back for every scheduled retest.

Keep every hearing retest on schedule

Pabau brings intake forms, audiogram records, and automated retest reminders into one patient record. Your team spots a missed monitoring test before an auditor or a patient does.

Book a demo

Conclusion

Start with the patients already on your books. Run current medication lists against the template, flag anyone on two ototoxic drugs or with impaired kidney function, and book their baselines first.

The payoff is timing. A shift caught at the high frequencies leaves the prescriber room to change course. One found after the patient notices muffled speech usually comes too late to reverse.

Serial testing does cost audiology time. Spend it on aminoglycosides and cisplatin, and rely on symptom reporting for lower-risk drugs such as NSAIDs.

Book a demo to see how Pabau keeps baselines, retest dates, and referral notes on one record for your audiology team.

Continue your research

Treating patients with rheumatoid arthritis? RA medication list groups each drug by class with its dose, monitoring labs, and review date.

Managing lupus patients on hydroxychloroquine? SLE medication list organizes lupus drugs by class, with dosing and monitoring for each.

Need a quick reference for each high-risk drug? Drug card template fits dose, contraindications, and nursing notes for one drug onto a two-page card.

Caring for patients on cisplatin? Cancer nursing care plan sets out assessment, diagnoses, goals, interventions, and evaluation for oncology patients.

Moving screening records off paper? Best clinical documentation software compares six platforms by practice type, from AI scribes to all-in-one systems.

Frequently asked questions